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Duration of Triple TherapyA Clinical Question Yet to Be AnsweredWe commend the authors of the recently pub-
lished ISAR-TRIPLE (Duration of Triple Therapy in
Patients Requiring Oral Anticoagulation After Drug
Eluting Stent Implantation) clinical trial on their
efforts (1). The trial adds valuable information
to the ongoing debate of antiplatelet and
anticoagulation management in patients on chronic
oral anticoagulation who undergo coronary artery
stenting; however, we would like to address several
important points:
1. The authors mention that the clopidogrel loading
dose was 300 mg to 600 mg, but they do not
mention speciﬁc data about the loading dose in
each of the treatment arms. Given the numeri-
cally higher periprocedural myocardial infarctions
observed in the 6-weeks group, could a prefer-
ential lower clopidogrel loading dose have
affected this outcome? It would be interesting to
know such data, as well as the repeat revascu-
larization data.
2. There are no data about the prevalence of chronic
kidney disease in each of the 2 treatment arms.
Chronic kidney disease patients are prone to a
higher risk of bleeding, and thus it is important to
know whether such data could have affected the
results.
3. The decision to present 9-month data as opposed
to longer follow-up, especially with the relatively
small sample, raises questions about the power
of the study to depict differences in ischemic
outcomes.
In conclusion, the optimal duration of triple ther-
apy is a question that remains unanswered, and for
now, mostly relies on physicians weighing the
ischemic versus bleeding risk with short compared to
extended duration of therapy. A large, randomized
trial comparing these various treatment options is
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REPLY: Duration of Triple TherapyA Clinical Question Yet to Be AnsweredWe thank Dr. Nairooz and colleagues for the com-
ments regarding the results of our ISAR TRIPLE trial
(Duration of Triple Therapy in Patients Requiring Oral
Anticoagulation After Drug Eluting Stent Implanta-
tion) (1) and are happy to provide our answers to his
3 questions:
1. Only 5% of the patients (n ¼ 30) in the ISAR TRIPLE
trial were loaded with 300-mg clopidogrel, and
they were evenly distributed in the 2 study arms.
Interestingly, all patients who developed myocar-
dial infarction had a loading dose of 600-mg
clopidogrel.
2. The lack of treatment effect regarding the primary
combined endpoint was consistent in the pre-
speciﬁed subgroup analysis according to renal
function and this, as well as the prevalence of
reduced renal function, was already shown in
Online Figure 2. Dr. Nairooz and colleagues are
concerned that patients with chronic kidney dis-
ease may have experienced higher bleeding rates;
however, there was also no association with renal
function and the occurrence of the secondary
endpoint Thrombolysis In Myocardial Infarction
major bleeding (p for interaction ¼ 0.89) or any
bleeding according to Bleeding Academic Research
Consortium (p for interaction ¼ 0.70).
3. A longer follow-up period for the evaluation of
treatment effect would have been inappropriate
because the protocol did not deﬁne differences in
antiplatelet therapy after 6 months in the 2 study
arms. Thus, ischemic complications occurring after
